44 results about "Connective tissue cell" patented technology

A resorbable, flexible implant in the form of a continuous macro-porous sheet is disclosed. The implant is adapted to protect biological tissue defects, especially bone defects in the mammalian skeletal system, from the interposition of adjacent soft tissues during in vivo repair. The membrane has pores with diameters from 20 microns to 3000 microns. This porosity is such that vasculature and connective tissue cells derived from the adjacent soft tissues including the periosteum can proliferate through the membrane into the bone defect. The thickness of the sheet is such that the sheet has both sufficient flexibility to allow the sheet to be shaped to conform to the configuration of a skeletal region to be repaired, and sufficient tensile strength to allow the sheet to be so shaped without damage to the sheet. The sheet provides enough inherent mechanical strength to withstand pressure from adjacent musculature and does not collapse.

A resorbing, flexible implant in the form of a continuous macro-porous sheet (42) is disclosed. The implant is adapted to protect biological tissue defects, especially bone defects in the mammalian skeletal system, from the interposition of adjacent soft tissues during in vitro repair. The membrane (42) has pores with diameters from 20 microns to 3000 microns. This porosity is such that vasculature, and connective tissue cells derived from the adjacent soft tissues including the periosteum, can proliferate through the membrane into the bone defect. The thickness of the sheet is such that the sheet has both sufficient flexibility to allow the sheet to be shaped to conform to the configuration of a skeletal region to be repaired, and sufficient tensile strength to allow the sheet to be so shaped without damage to the sheet. The sheet provides enough inherent mechanical strength to withstand pressure from adjacent musculature, and does not collapse.

A resorbable, flexible implant in the form of a continuous macro-porous sheet is disclosed. The implant is adapted to protect biological tissue defects, especially bone defects in the mammalian skeletal system, from the interposition of adjacent soft tissues during in vivo repair. The membrane has pores with diameters from 20 microns to 3000 microns. This porosity is such that vasculature and connective tissue cells derived from the adjacent soft tissues including the periosteum can proliferate through the membrane into the bone defect. The thickness of the sheet is such that the sheet has both sufficient flexibility to allow the sheet to be shaped to conform to the configuration of a skeletal region to be repaired, and sufficient tensile strength to allow the sheet to be so shaped without damage to the sheet. The sheet provides enough inherent mechanical strength to withstand pressure from adjacent musculature and does not collapse.

For promoting tissue regeneration on wound surfaces (1) mechanical oscillation is coupled into the wound surfaces. A treatment instrument (2) coupled to an oscillation drive is brought into contact with the wound surface (1), or an implant is impinged with oscillation during and / or after being positioned in the tissue. The oscillation acts mechanically and thermally on the tissue in the region of the treated wound surface (1), and according to the intensity acts in a stimulating, traumatic, necrotic or cell-destroying manner. Therefore, biological elements inhibiting tissue regeneration are destroyed or denatured and the metabolism in the region of the wound surface is stimulated. The effect may also be a mechanical one, slightly compacting or regionally dislocating the tissue. Since the treatment can be effected during or after positioning an implant, necrosis in particular effects undesired cells, such as connective tissue cells, mucous cells and diseased cells having been brought to the wound surface with the implant, which cells may inhibit the intergrowth between tissue and implant.

Disclosed are engineered, living, three-dimensional connective tissue constructs comprising connective tissue cells. In some embodiments, the connective tissue cells are derived from multi-potent cells such as mesenchymal stem / stromal cells. In some embodiments, the cells are cohered to one another. In some embodiments, the multi-potent cells have been exposed to one or more differentiation signals to provide a living, three-dimensional connective tissue construct. In some embodiments, the constructs are substantially free of pre-formed scaffold at the time of use. Also disclosed are implants for engraftment, arrays of connective tissue constructs for in vitro experimentation, as well as methods of making the same.

Compositions and methods are provided for modulating the growth, development and repair of bone, cartilage or other connective tissue. Devices and stimulus waveforms are provided to differentially modulate the behavior of osteoblasts, chondrocytes and other connective tissue cells to promote proliferation, differentiation, matrix formation or mineralization for in vitro or in vivo applications. Continuous-mode and pulse-burst-mode stimulation of cells with charge-balanced signals may be used. Bone, cartilage and other connective tissue growth is stimulated in part by nitric oxide release through electrical stimulation and may be modulated through co-administration of NO donors and NO synthase inhibitors. Bone, cartilage and other connective tissue growth is stimulated in part by release of BMP-2 and BMP-7 in response to electrical stimulation to promote differentiation of cells. The methods and devices described are useful in promoting repair of bone fractures, cartilage and connective tissue repair as well as for engineering tissue for transplantation.

Compositions and methods are provided for modulating the growth, development and repair of cartilage, bone or other connective tissue. Devices and stimulus waveforms are provided to differentially modulate the behavior of chondrocytes, osteoblasts and other connective tissue cells to promote proliferation, differentiation, matrix formation or mineralization for in vitro or in vivo applications. Continuous-mode and pulse-burst-mode stimulation of cells with charge-balanced signals may be used. Cartilage, bone and other connective tissue growth is stimulated in part by nitric oxide release through electrical stimulation and may be modulated through co-administration of NO donors and NO synthase inhibitors. The methods and devices described are useful in promoting repair of bone fractures, cartilage and connective tissue repair as well as for engineering tissue for transplantation.

Disclosed is a method for distinguishing a mesenchymal stem cell comprising, using at least one gene selected from the genes having the nucleotide sequences indicated by the accession numbers shown in Table 1 as a distinguish marker, detecting the difference in expression of the distinguish marker between a mesenchymal stem cell and a connective tissue cell to distinguish the mesenchymal stem cell from the connective tissue cell. This method enables to distinguish an undifferentiated mesenchymal stem cell from other connective tissue cell such as fibroblasts, osteoblasts, chondrocytes and adipose cells with good accuracy. A mesenchymal stem cell given by this method or a composition comprising the mesenchymal stem sell can be used as a therapeutic for use in the regenerative medicine.

Compositions and methods are provided for modulating the growth, development and repair of bone, cartilage or other connective tissue. Devices and stimulus waveforms are provided to differentially modulate the behavior of osteoblasts, chondrocytes and other connective tissue cells to promote proliferation, differentiation, matrix formation or mineralization for in vitro or in vivo applications. Continuous-mode and pulse-burst-mode stimulation of cells with charge-balanced signals may be used. Bone, cartilage and other connective tissue growth is stimulated in part by nitric oxide release through electrical stimulation and may be modulated through co-administration of NO donors and NO synthase inhibitors. Bone, cartilage and other connective tissue growth is stimulated in part by release of BMP-2 and BMP-7 in response to electrical stimulation to promote differentiation of cells. The methods and devices described are useful in promoting repair of bone fractures, cartilage and connective tissue repair as well as for engineering tissue for transplantation.

Methods and devices are disclosed for processing stromal precursor cells (i.e., cells which can differentiate into connective tissue cells, such as in muscles, ligaments, or tendons) which can be obtained from fatty tissue extracts obtained via liposuction. Normal processing of a liposuction extract involves centrifugation, to concentrate the stromal cells into a semi-concentrated form called “spun fat”. That “spun fat” can then be treated by mechanical processing (such as pressure-driven extrusion through 0.5 mm holes) under conditions which can gently pry the stromal cells away from extra-cellular collagen fibers and other debris in the “spun fat”. The extruded mixture is then centrifuged again, to separate a highly-enriched population of stromal cells which is suited for injection back into the patient (along with platelet cells, if desired, to further promote tissue repair or regeneration).

An endosseous dental implant for guided regeneration of gingival tissue onto the implant and method of producing the same is prepared by coating a region of the implant with biocompatible, random or aligned microfibers or nanofibers to which gingival epithelial and connective tissue cells may become attached. The fibers may be degradable or nondegradable. The extracellular matrix of new connective tissue forms and connects to the implant surface, guided by the nanofibers or microfibers. The coated implant prevents bacterial biofilm formation, which can cause detrimental resorption of crestal bone and lead to implant failure. The implant surface supports improved tissue bonding and provides a cost-effective approach to coating the dental implant surface with biomimetic fibers to enhance gingival or other tissue regeneration directly onto the implant surface.

The invention provides an ovarian cell microcapsule, which adopts alginate-poly-lysine- alginate (APA) to encapsulate ovarian cells and prepare a microcapsule containing ovarian cells inside. The ovarian cells in the microcapsule consists of ovarian granulosa cells and theca cells, which has endocrine function; undifferentiated ovary inner mesenchymal cells and connective tissue cells. If allogenously plant the microcapsule of the invention, the endocrine cells in the microcapsule can constantly secret sex hormone in body, and the endocrine function can be under the control of neuroendorine of the body to reach the aim of personalized supplementing the inefficiency of sex hormone endocrine. The allogenous plant of ovarian cell microcapsule has positive prevention and treatment effects to body degenerative lesion. Experiment shows that the invention can alleviate the loss of bone quantity and presents positive effect to the prevention and treatment of osteoporosis; meanwhile, the invention can affect the biological activity of islet Alpha cell and Beta cell, and regulate the endocrine of insulin and glucagons.

A gingival attachment device associated with an endosseous implant, which comprises a cervically located component of a dental implant coated on a gingival facing surface thereof with a biocompatible and non-degradable polymeric scaffold, to which epithelial and connective tissue cells of the gingiva are attachable. The polymeric scaffold may be polyvinylpyrronidole mixed with butyl-methylmethacrylate, silk fibroin fibrous protein polymer mixed with chitosan or with derivatives of chitosan, and polyHEMA and may be coated on all gingival facing surfaces of the cervically located component.

The present invention describes an in vitro / ex vivo method for the cultivation of connective tissue cells or progenitor cells (e.g. chondrogenic cells) in matrix comprising polysulphated alginate. These cultivated cells can be used in the preparation of a medicament for the treatment or prevention of osteochondral defects. The invention also describes a matrix comprising polysulphated alginate and mammalian connective tissue cells or progenitor cells thereof.

The present invention provides compositions and methods for modulating the growth, development, and repair of bone, cartilage, or other connective tissue. Also provided are devices and stimulation waveforms to differentially modulate the behavior of osteoblasts, chondrocytes, and other connective tissue cells to promote proliferation, differentiation, matrix formation, or mineralization for in vitro or in vivo applications. Continuous mode and pulsed segment mode of cell stimulation with charge-balanced signals can be used. Bone, cartilage, and other connective tissue growth is stimulated in part by the release of nitric oxide via electrical stimulation, and can be regulated by simultaneous supply of NO donors and NO synthase inhibitors. Bone, cartilage and other connective tissue growth is stimulated in part by the release of BMP-2 and BMP-7 in response to electrical stimulation that promotes cell differentiation. The methods and devices are useful for promoting bone fracture repair, cartilage and connective tissue repair, and for engineering tissue for transplantation.

De-differentiation protocols are described herein for generating progenitor cells from adult connective tissue, in particular adult human fibroblasts. The de-differentiation protocols described herein comprise culturing the differentiated cells with an amount of FGF2 to de-differentiate the cells. These de-differentiated cells may then be cultured and used for experimentation, amplification and clinical applications. The clinical applications include the use of the cells for tissue and cell based therapies.

The fast hymen regenerating and repairing medicine is prepared with hemoglobin 15-30 weight portions, lecithin 10-20 weight portions, amino acid 15-25 weight portions, albumin glue 2-10 weight portions, notoginseng 2-10 weight portions, saffron 1-8 weight portions, protein 5-15 weight portions, cellulose 10-20 weight portions, and free coagulase 5-15 weight portions. The present invention is used in the local targeting process to provide hymen root cell with nutritious components and active growth elements, to activate cells for division and regeneration and to regenerate hymen. The present invention has excellent treating effect.

The invention provides a cattle trophoderm stem cell system establishment method which comprises the following steps: inoculating hemiblastula of which zona pellucida is removed through pronase treatment into a feed layer in mouse embryonic fibroblast subjected to mitomycin treatment and Wnt-3A mouse subcutaneous connective tissue cells, adding 2i small-molecule inhibitor culture solution to perform continuous cell culture of cells, and establishing a cattle trophoderm stem cell system. The method can be used for obtaining and culturing cattle trophoderm stem cells under in-vitro conditions for a long time. The cattle trophoderm stem cell system establishment method can be applied to large animal transgenosis and somatic cell cloning and can be further used for cattle embryo implantation and placenta differentiation.

The application discloses a method for making bone at a bone defect site for a person suffering from low bone mass which includes inserting a gene encoding a protein having bone regenerating function into a connective tissue cell operably linked to a promoter, and transplanting the mammalian cell into the bone defect site, and allowing the bone defect site to make the bone.

Biological tissues are grown in a low shear, microgravity environment by culturing connective tissue cells to form a three-dimensional structure, which is thereafter co-cultured with endothelial and epithelial cells to replicate naturally occurring tissues. Preferably, the three-dimensional connective tissue cells are first cultured with endothelial cells to form three-dimensional structures of connective tissue cells and endothelial cells, which are thereafter co-cultured with epithelial cells to replicate naturally occurring tissue. The cultured tissue is in the general shape of spheroids having a diameter between about 0.1 mm and about 5 m.

The subject invention is directed to a composition comprising primed connective tissue cells and a pharmaceutically acceptable carrier thereof.

The invention discloses a preparation method of hairtail active extract for repairing bone joints; the preparation method comprises the steps of enzyme complex hydrolysis, multistage membrane filtration, nanofiltration, HPLC (high-performance liquid chromatography) eluting and lyophilizing; the step of enzyme complex hydrolysis includes enzymatically hydrolyzing hairtail flesh homogenate via Bacillus marinus alkali-producing proteinase and Porphyra yezoensis proteinase, and performing ultrasonic-assisted enzymatic hydrolysis. The preparation method has the advantages that marine organism proteins are greatly differed from terrestrial life proteins in both amino acid composition and amino acid sequence and hairtail proteins can be enzymatically hydrolyzed via the Bacillus marinus alkali-producing proteinase and Porphyra yezoensis proteinase to obtain mass active peptides; the obtained hairtail active extract can promote the generation of cartilage cells, joint synovial fluid can be massively induced and supplemented, the generation of collagen matrix can be effectively promoted, regeneration of connective tissue cells is stimulated, and the reconstruction and recovery of soft tissues are accelerated accordingly.

Disclosed is a method for distinguishing a mesenchymal stem cell comprising, using at least one gene selected from the genes having the nucleotide sequences indicated by the accession numbers shown in Table 1 as a distinguish marker, detecting the difference in expression of the distinguish marker between a mesenchymal stem cell and a connective tissue cell to distinguish the mesenchymal stem cell from the connective tissue cell. This method enables to distinguish an undifferentiated mesenchymal stem cell from other connective tissue cell such as fibroblasts, osteoblasts, chondrocytes and adipose cells with good accuracy. A mesenchymal stem cell given by this method or a composition comprising the mesenchymal stem sell can be used as a therapeutic for use in the regenerative medicine.

The invention discloses a hairtail activity extract for articulation restoration. The hairtail activity extract is prepared by compound enzyme enzymolysis, multi-stage membrane filtration, nanofiltration, HPLC (High Performance Liquid Chromatography) elution and freeze drying, wherein the compound enzyme enzymolysis comprises the steps of performing enzymolysis on hairtail meat homogenate by adopting marine bacillus produced alkaline protease and porphyra yezoensis protease, and performing ultrasonic for assisting in the enzymolysis. The hairtail activity extract has the benefits that the composition and a sequence of amino acid of marine organism protein are very different from those of terrestrial organism protein; when the marine bacillus produced alkaline protease and the porphyra yezoensis protease simultaneously perform the enzymolysis on hairtail protein, abundant activated peptide fragments can be obtained; and the obtained hairtail activity extract can promote generation of cartilage cells, can greatly hasten and supplement articulation synovia, can effectively promote generation of collagen stroma, stimulates regeneration of connective tissue cells, and further accelerates reconstruction and recovery of a soft tissue.

The application discloses a method for making bone at a bone defect site for a person suffering from low bone mass which includes inserting a gene encoding a protein having bone regenerating function into a connective tissue cell operably linked to a promoter, and transplanting the mammalian cell into the bone defect site, and allowing the bone defect site to make the bone.

The invention belongs to the field of pharmaceutics and relates to formulations for external use for the treatment of peripheral joints, spinal joints and / or extracellular matrix elements of connective tissue. The claimed formulation provides for superior (in comparison to existing analogs) transdermal delivery of pharmaceutically active ingredients, in particular, glucosamine sulfate or other glucosamine salts, and additional ingredients to affected joints. Also proposed is a method of producing said formulation and therapeutic use thereof. The efficacy of the proposed formulation is confirmed by clinical test results.